8-K - iBio, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

iBio, Inc. announced preclinical body composition data from its obese non-human primate study of IBIO-610, showing 6.7% visceral fat reduction and 5.2% total fat mass reduction after two once-every-eight-week doses in a small study. The company updated its corporate presentation describing strategic expansion into the cardiopulmonary space targeting PH-HFpEF with its myostatin x Activin A bispecific antibody program.

Key Takeaways

1IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in obese NHPs vs vehicle-treated controls

2Study involved two once-every-eight-week dosings of IBIO-610 in small, not statistically powered obese NHP cohort

3IBIO-610 showed slight up-tick in lean mass following treatment

4Previously reported IBIO-610 half-life of 33.2 days in obese NHPs

5Corporate presentation updated to describe expansion into PH-HFpEF using myostatin x Activin A bispecific antibody

6Press release issued March 9, 2026, furnished as Exhibit 99.1

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securi

Regulation Fd

8.01

. Other Events. Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610 On March 9, 2026, the Company issued a press release a

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 9, 2026 99.2 Corporation Presentation of iBi

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2